Breast Cancer Research and Treatment

, Volume 32, Issue 2, pp 221–228 | Cite as

Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma

  • Cecilia Bozzetti
  • Rita Nizzoli
  • Nadia Naldi
  • Laura Manotti
  • Luisa Savoldi
  • Roberta Camisa
  • Annamaria Guazzi
  • Giorgio Cocconi


Fine-needle aspiration cytology has been already established as a reliable method for the diagnosis of breast cancer. Its application has been recently extended to immunocytochemical analysis of biological parameters. In the current study estrogen and progesterone receptors, Ki67 growth fraction, and p53 protein expression were immunocytochemically evaluated on the cellular material sampled by the same fine-needle aspirate used for the conventional cytologic diagnosis of malignancy. Fine-needle aspiration specimens from 100 patients with primary breast carcinoma were submitted to the immunocytochemical analysis. Twenty-eight percent were in premenopause; 23% had tumors with a diameter less than 2 cm, 59% from 2 to 5 cm, and 18% more than 5 cm; 60% had axillary nodal status negative, 34% positive, and 6% unknown. The concomitant immunocytochemical evaluation of all parameters was possible in 70% of the patients. A significant association was found between p53 overexpression and Ki67 values (p = 0.004), and between Ki67 values and progesterone receptor status (p = 0.003). No correlation was found between any parameter and clinical tumor size. Estrogen (p = 0.02) and progesterone (p = 0.04) receptor negativity and high Ki67 growth fraction (p = 0.005) were significantly associated with the clinical evidence of axillary node involvement. This study suggests that fine-needle aspiration cytology represents an effective practice for a simultaneous evaluation of multiple biologic indicators and could be useful as a preoperative procedure in patients who are candidates for neoadjuvant chemotherapy and/or endocrine therapy.

Key words

breast cancer estrogen and progesterone receptors Ki67 antigen p53 protein fine-needle aspiration cytology immunocytochemistry 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Franzèn F, Zajicek J: Aspiration biopsy in diagnosis of palpable lesions of the breast: critical review of 3479 consecutive biopsies. Acta Radiol 7: 241–262, 1968Google Scholar
  2. 2.
    Kline TS, Jaski L, Neal HS: Fine needle aspiration of breast: diagnosis and pitfalls. Cancer 44: 1458–1464, 1979Google Scholar
  3. 3.
    Reiner A, Neumeister B, Spona J, Reiner G, Schempen M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990Google Scholar
  4. 4.
    Kuenen-Boumeester V, Van der Kvast ThH, Van Laarhoven HAJ, Henzen-Logmans SC: Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. J Clin Pathol 44: 208–210, 1991Google Scholar
  5. 5.
    Koutselini H, Malliri A, Field JK, Spandidos DA: p53 expression in cytologic specimens from benign and malignant breast lesions. Anticancer Res 11: 1415–1419, 1991Google Scholar
  6. 6.
    Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1984Google Scholar
  7. 7.
    Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N, on behalf of the Danish Breast Cancer Cooperative Group: Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47: 6126–6133, 1987Google Scholar
  8. 8.
    Meyer JS, Friedman E, McCrate M, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983Google Scholar
  9. 9.
    Silvestrini R, Daidone MG, Gasparini G: Cell cycle kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985Google Scholar
  10. 10.
    Kallioniemi OP, Hietanen T, Mattila J, Lehtinen M, Lauslahti K, Koivula T: Aneuploid DNA content and high S phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 23: 277–282, 1987Google Scholar
  11. 11.
    Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H: Ki67 index and S-phase fraction in human breast carcinomas: comparison and correlation with prognostic factors. Am J Clin Pathol 94: 681–686, 1990Google Scholar
  12. 12.
    Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S: Ki67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421–428, 1991Google Scholar
  13. 13.
    Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453–456, 1991Google Scholar
  14. 14.
    Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: p53 expression in breast cancer. Int J Cancer 41: 178–183, 1988Google Scholar
  15. 15.
    Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010, 1991Google Scholar
  16. 16.
    Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109–1114, 1992Google Scholar
  17. 17.
    Davidoff AM, Herndon JE II, Glover NS, Kerns BJM, Pence JC, Iglehart JD, Marks JR: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259–264, 1991Google Scholar
  18. 18.
    Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall B, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845–855, 1992Google Scholar
  19. 19.
    Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206, 1993Google Scholar
  20. 20.
    Zajicek J: Sampling of cells from human tumours by aspiration biopsy for diagnosis and research. Eur J Cancer 1: 253–258, 1965Google Scholar
  21. 21.
    Greene GL, Sobeil NB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51–56, 1984Google Scholar
  22. 22.
    Press MF, Greene GL: Localization of progesterone receptor with monoclonal antibodies to the human progesterone receptor. Endocrinology 122: 1165–1175, 1988Google Scholar
  23. 23.
    Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20, 1983Google Scholar
  24. 24.
    Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529–534, 1986Google Scholar
  25. 25.
    McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary nodenegative breast cancer patients. J Natl Cancer Inst 82: 1006–1015, 1990Google Scholar
  26. 26.
    Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181–187, 1989Google Scholar
  27. 27.
    Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER & cooperating investigators: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52: 1551–1557, 1983Google Scholar
  28. 28.
    Masood S: Use of monoclonal antibody for assessment of estrogen receptor content in fine-needle aspiration biopsy specimens from patients with breast cancer. Arch Pathol Lab Med 113: 26–30, 1989Google Scholar
  29. 29.
    Silfversward C, Humla S: Estrogen receptor analysis on needle aspirates from human mammary carcinoma. Acta Cytol 24: 54–57, 1980Google Scholar
  30. 30.
    Flowers JL, Burton GV, Cox EB, McCarty KS Sr, Dent GA, Geisinger KR, McCarty KS Jr: Use of monoclonal antiestrogen receptor antibody to evaluate estrogen receptor content in fine needle aspiration breast biopsies. Ann Surg 203: 250–254, 1986Google Scholar
  31. 31.
    Lozowsky M, Greene G, Sadri D, Stanick D, Pai P, Harris MA, Lundy J: The use of fine needle aspirates in the evaluation of progesterone receptor content in breast cancer. Acta Cytol 34: 27–30, 1990Google Scholar
  32. 32.
    Charpin C, Andrac L, Habib MC, Vacheret H, Xerri L, Devictor B, Lavaut MN, Toga M: Immunodetection in fine-needle aspirates and multiparametric (SAMBA) image analysis. Cancer 63: 863–872, 1989Google Scholar
  33. 33.
    Shohat O, Greenberg M, Reisman D, Oren M, Rotter V: Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene 1: 277–283, 1987Google Scholar
  34. 34.
    Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, Theillet C: p53 mutations occur in aggressive breast cancer. Cancer Res 52: 3918–3923, 1992Google Scholar
  35. 35.
    McGurrin JF, Doria MI, Dawson PJ, Karrison T, Stein HO, Franklin WA: Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 59: 1744–1750, 1987Google Scholar
  36. 36.
    Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943–947, 1989Google Scholar
  37. 37.
    Gerdes J, Pickartz H, Brotherton J, Hammerstein J, Weitzel H, Stein H: Growth fractions and estrogen receptors in human breast cancers as determinedin situ with monoclonal antibodies. Am J Pathol 129: 486–492, 1987Google Scholar
  38. 38.
    Raymond WA, Leong ASY: The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining. J Pathol 8: 203–211, 1989Google Scholar
  39. 39.
    Wrba F, Chott A, Reiner A, Reiner G, Markis-Ritzinger E, Holzner JH: Ki67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. Oncology 46: 255–259, 1989Google Scholar
  40. 40.
    Vollmer G, Gerdes J, Knuppen R: Relationship of cytosolic estrogen and progesterone receptor content and the growth fraction in human mammary carcinomas. Cancer Res 49: 4011–4014, 1989Google Scholar
  41. 41.
    Lellé RJ, Heidenreich W, Stauch G, Gerdes J: The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer 59: 83–88, 1987Google Scholar
  42. 42.
    Kuenen-Boumeester W, Blonk DI, Van der Kwast ThH: Immunocytochemical staining of proliferating cells in fine needle aspiration smears of primary and metastatic breast tumours. Br J Cancer 57: 509–511, 1988Google Scholar
  43. 43.
    Katz RL, Patel S, Sneige N, Fritsche HA Jr, Hortobagyi GN, Ames FC, Brook ST, Ordonez NG: Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 15: 191–203, 1990Google Scholar
  44. 44.
    Bevilacqua P, Pea M, Gasparini G: Immunocytochemical detection of progesterone receptor by monoclonal KD-68 antibody in operable breast cancer: correlations with biochemical assay, pathological features and cell proliferative rate. Eur J Cancer Clin Oncol 25: 1595–1602, 1989Google Scholar
  45. 45.
    Reiner A, Reiner G, Spona J, Schemper M, Holzner JH: Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. Cancer 61: 1149–1154, 1988Google Scholar
  46. 46.
    Ozzello L, DeRosa C, Habif DV, Greene GL: An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 67: 455–462, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Cecilia Bozzetti
    • 1
  • Rita Nizzoli
    • 1
  • Nadia Naldi
    • 1
  • Laura Manotti
    • 1
  • Luisa Savoldi
    • 1
  • Roberta Camisa
    • 1
  • Annamaria Guazzi
    • 1
  • Giorgio Cocconi
    • 1
  1. 1.Division of Medical OncologyUniversity HospitalParmaItaly

Personalised recommendations